DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as eight ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy 1, reinforcing the need to broaden ...